• MASH: molecular underpinnings of novel therapeutics Percy Knolle 
• Lipoproteins and their role in hepatitis virus replication and liver disease Ralf Bartenschlager
• Oral Presentation
• Oral Presentation: A MOST RELEVANT MODEL OF HEPATITIS C VIRUS (HCV) INFECTION IN PRIMARY HUMAN HEPATOCYTES REVEALS THAT ALCOHOL INCREASES THE PRODUCTION OF BOTH VERY-LOW-DENSITY LIPOPROTEINS (VLDL) AND HIGHLY INFECTIOUS LIPO-VIRO-PARTICLES Arielle Rosenberg 
• Oral Presentation: EVALUATION OF CELL FREE DNA METHYLATION AS LIQUID BIOPSY BIOMARKER TO DIFFERENTIATE HEPATITIS B VIRUS INDUCED HEPATOCELLULAR CARCINOMA FROM CHRONIC LIVER DISEASE Baibaswata Nayak
• Q&A

• Interferon as a Component of HBV Cure in 2024 and 2034  Harry Janssen
• Oral Presentation: IMMUNE SIGNATURE ASSOCIATED WITH VIRAL SUPPRESSION FOLLOWING NUCLEOS(T)IDE ANOLOGUE TREATMENT IN ADULTS LIVING WITH CHRONIC HBV INFECTION IN SOUTH AFRICA Marion Delphin
• Oral Presentation: SIMILAR RATES OF BIOCHEMICAL RESPONSE ARE OBSERVED ACROSS VIROLOGIC RESPONSE CATEGORIES OVER 96 WEEKS OF BULEVIRTIDE Renee-Claude Mercier
• Oral Presentation: FACTORS INFLUENCING HEPATITIS B SPECIALITY CARE REFERRAL AMONG REFUGEES RECENTLY RESETTLED TO THE UNITED STATES Erin Mann
• Oral Presentation: CHALLENGES AND OPPORTUNITIES FOR REENGAGING DIAGNOSED BUT UNTREATED HBV/HCV-INFECTED INDIVIDUALS IN THE UNITED STATES TO CARE (PRELIMINARY RESULTS FROM A MULTI-CENTER RELINK PROGRAM) Helen Nde
• Q&A

• How to Engage and Support Priority Populations for Viral Hepatitis Care in Non-Endemic Regions Christina Greenway 
• Patient and Provider Perspective on Overcoming Barriers to Care Su Wang
• Oral Presentation: FACTORS INFLUENCING ANTIVIRAL MEDICATION ADHERENCE AMONG CHRONIC HEPATITIS B PATIENTS IN ADDIS ABABA: A MULTICENTER CROSS-SECTIONAL STUDY  Kaleb Berhane
• Oral Presentation: DEVELOPMENT AND IMPLEMENTATION OF AN HEPATITIS D DETECTION AND LINKAGE TO CARE PROGRAM IN CATALONIA. PRELIMINARY RESULTS.  Maria Buti
• Oral Presentation: IMPACT OF SYSTEMATIC SCREENING FOR VIRAL HEPATITIS IN THE ED: A FOUR-YEAR PROSPECTIVE STUDY Maria Buti 
• Q&A

• Oral Presentation: PREVALENCE AND CORRELATES OF HEPATITIS C IN A MALAYSIAN PRISON Mahija Ginjupalli
• Oral Presentation: PREVALENCE OF HBV AND HCV INFECTIONS AMONG AT-RISK MIGRANT AND REFUGEE POPULATIONS IN GREECE, ITALY AND SPAIN: 2-YEAR RESULTS OF THE VH-COMSAVAC PROJECT Camila Picchio
• Oral Presentation: INTERVENTIONS TO IMPROVE TESTING, LINKAGE TO CARE, AND TREATMENT UPTAKE FOR HEPATITIS C INFECTION IN PRISON: A SYSTEMATIC REVIEW Jason Grebely
• Q&A

• Prevention of hepatitis B and D (including PMTCT- increasing HBV birth dose, novel strategies to treat any woman HbsAg+ if no HBV DNA or birth dose available) Ben Cowie 
• Prevention of hepatitis C (focus on PWID – known interventions that are effective, such as opioid agonist treatment and syringe service programs) Julie Bruneau
• Oral Presentation: MODELING THE EFFECT OF TARGETED INTERVENTIONS ON THE SPREAD OF HEPATITIS C THROUGH A NETWORK OF PEOPLE WHO INJECT DRUGS IN KENYA Ewan Colman
• Oral Presentation: OPTIMIZING TESTING AND TREATMENT STRATEGIES FOR HEPATITIS C ELIMINATION IN PUNJAB, PAKISTAN; REPORT FROM HEPATITIS PREVENTION AND TREATMENT PROGRAM Saeed Akhter
• Oral Presentation: IMPACT OF A TREATMENT PEER-SUPPORT MODEL ON HEPATITIS B SCREENING AND LINKAGE TO INTEGRATED HIV/HBV CARE IN A HIGH BURDEN HBV SETTING IN NORTHERN UGANDA Joan J. Mutyoba
• Oral Presentation: CHARACTERIZING ENGAGEMENT IN HEPATITIS C VIRUS TESTING AND CARE FOR INFANTS BORN TO PERSONS WHO TEST POSITIVE FOR HCV IN ONTARIO, CANADA Andrew B. Mendlowitz
• Q&A

• Report Card on Drug Development for HBV: Lessons Learned and the Path Forward + Q&A  Ed Gane
• Oral Presentation: ANTI-HBSAG MONOCLONAL ANTIBODY BJT-778 DEMONSTRATES PANGENOTYPIC NEUTRALIZATION OF HEPATITIS B AND D VIRUSES  + Q&A Ronald Alcala
• Oral Presentation: HBSAG LOSS IN INACTIVE CHRONIC HEPATITIS B CARRIERS IS DEPENDENT ON LEVEL OF QHBSAG AND INTERFERON RESPONSE: A RANDOMISED CONTROL TRIAL + Q&A  Seng Gee Lim
• Introductory Talk: Current & future therapies from a global perspective (challenges & barriers) Funmi Lesi
• Panel - HBV Therapeutics (what's needed now and in the future) + Q&A

Moderator: Ju Dong Yang

• Risk stratification – HBV and post-SVR  Nicole Kim
• Debate – Are there patients that we can stop surveillance in low risk patients? Neil Mehta, Nicole Kim
• Early detection/screening – surveillance underuse and emerging modalities Ju Dong Yang
• Panel – implementation of these strategies   Neil Mehta, Nicole Kim, Ju Dong Yang

• Optimising strategies to enhance screening and diagnosis for hepatitis B Jean-Michel Pawlotsky 
• Optimising strategies to enhance screening and diagnosis for hepatitis C (lab-based testing, point-of-care testing, dried-blood spot testing, self-testing)  
• Oral Presentation: EFFECTIVENESS OF HEALTH SYSTEM INTERVENTIONS ON UPTAKE OF HEPATITIS C SELF-TESTING (HCV-ST) IN URBAN SLUMS OF HARIDWAR: A PRAGMATIC CLUSTER RANDOMIZED CONTROL TRIAL Ajeet Singh
• Oral Presentation: LOW LEVELS OF VIRAL HEPATITIS AWARENESS, TESTING, AND HBV VACCINATION AMONG AT-RISK MIGRANT AND REFUGEE POPULATIONS IN GREECE, ITALY AND SPAIN: RESULTS FROM VH-COMSAVAC Camilla Picchio
• Oral Presentation: BENDING THE CURVE OF HEPATITIS C VIRUS INFECTION IN MACHAR COLONY: A MASS SCREEN AND TREAT INTERVENTION IN A SLUM SETTLEMENT IN KARACHI, PAKISTAN Muhammad Khawar Aslam
• Oral Presentation: PREP PROGRAMMES AS A FRAMEWORK FOR TACKLING HBV INFECTION IN ADOLESCENTS AND YOUNG ADULTS IN KWAZULU-NATAL, SOUTH AFRICA Gloria Sukali
• Q&A

• Progress towards a Sterilizing Cure - Advances in Gene editing and Targeting cccDNA Fabien Zoulim
• The Role of RNA interference (siRNA, ASO) as the backbone of HBV Cure strategies Kosh Agarwal
• Therapeutic Vaccines and Other Immune Targets for Functional Cure, How Good is the Promise? Adam Gehring
• Oral Presentation: ASSOCIATION OF HEPATITIS B SURFACE ANTIGEN LOSS WITH CLINICAL OUTCOMES AMONG PATIENTS WITH CHRONIC HEPATITIS B INFECTION: A RETROSPECTIVE COHORT STUDY IN THE UNITED STATES Anna Coutinho
• Oral Presentation: TREATMENT RELATED NORMALIZATION OF ALT IS ASSOCIATED WITH RESOLUTION OF SIGNIFICANT LIVER INFLAMMATION IN PATIENTS WITH CHRONIC HEPATITIS B Lisa van Velsen
• Q&A

• Bulevirtide (BLV) as Monotherapy or Combination Treatment with Interferon for Hepatitis Delta Maria Buti
• Overview of New Drug Development for Hepatitis Delta Pietro Lampertico
• Management of Delta for indigenous populations Thor Dantas
• Oral Presentation: EFFICACY AND SAFETY OF BLV MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: POSTTREATMENT RESULTS THROUGH 48 WEEKS AFTER THE END OF TREATMENT FROM AN INTERIM ANALYSIS OF A RANDOMIZED PHASE 3 STUDY MYR301 Pietro Lampertico
• Oral Presentation: SAFETY AND EFFICACY OF REP 2139-MG IN HEPATITIS D PATIENTS: REPORTING OF EXTENDED FOLLOW-UP DATA FROM THE INTERNATIONAL COMPASSIONATE USE PROGRAM Christiane Stern
• Q&A

• Interventions to enhance linkage to hepatitis C care and treatment (not diagnostic strategies - e.g. electronic medical record audit, financial incentives, peer support, pharmacy starter packs) Seun Falade-Nwulia 
• Interventions to enhance linkage to hepatitis B & D care and treatment (not diagnostic strategies) Alexander Stockdale
• Oral Presentation: LINKAGE TO CARE OF PEOPLE WHO INJECT DRUGS WITHIN NATIONAL HEPATITIS C ELIMINATION PROGRAM IN GEORGIA Maka Gogia
• Oral Presentation: EVALUATING THE IMPACT OF INCREASED PROVISION OF LOW DEAD SPACE SYRINGES ON HIV AND HCV TRANSMISSION AMONG PEOPLE WHO INJECT DRUGS: A MODELLING ANALYSIS FOR 19 COUNTRIES Peter Vickerman
• Oral Presentation: OPTIMIZING HEALTHCARE SYSTEMS FOR VIRAL HEPATITIS ELIMINATION: AUTOMATING EMR-BASED HEPATITIS B AND C SCREENING Su Wang
• Oral Presentation: ACHIEVEMENTS AND CHALLENGES IN SCALING HCV SERVICES TO PRIMARY HEALTHCARE (PHC) FACILITIES IN CAMBODIA Alethea Tan
• Q&A

• Molecular basis for an HBV cure using antivirals Chloe Thio
• From controlling HDV to HDV cure Marc Ghany
• Oral Presentation: A NOVEL LONG-ACTING HBV/HDV ENTRY INHIBITOR Jimmy Zhang
• Oral Presentation: DEVELOPMENT AND VALIDATION OF STREAMLINED SERODIAGNOSIS OF HEPATITIS DELTA VIRUS ND Dashdorj
• Oral Presentation: VALUATION OF MIR-122 SERUM EXPRESSION AMONG INDIVIDUALS WITH LONG COVID AND VIRAL HEPATITIS Livia Villar
• Q&A

• Debate: Do Not Stop Long-Term NA Therapy in Absence of Functional Cure (against) Anna Lok
• Debate: You Can Stop Long-Term Therapy in Absence of Functional Cure (for) Rachel Jeng
• What is the Evidence for Expanding NA Therapy Patrick Kennedy
• Oral Presentation: EARLY OFF-TREATMENT HBCRAG AND ANTI-HBC LEVELS IDENTIFY PATIENTS AT HIGH RISK OF SEVERE ALT FLARES AFTER NUCLEOS(T)IDE ANALOGUE WITHDRAWAL – A POOLED ANALYSIS OF TWO PROSPECTIVE STUDIES Edo Dongelmans
• Oral Presentation: HEPATOCELLULAR CARCINOMA RISK IN HISPANICS WITH CHRONIC HEPATITIS B Ariel Lee
• Oral Presentation: HBV-HIV CO-INFECTION & TENOFOVIR INTERRUPTION IN THE UNITED STATES: MONITORING PRACTICES AND INCIDENCE OF HEPATITIS B REACTIVATION OR HEPATITIS FLARE Douglas T. Dieterich
• Q&A

• Corrections/Jails Nadine Kronfli
• Addressing Challenges to Engage People who Use Drugs into Care - A Community Perspective Sione Crawford
• Overseas born/refugees/migrants - Overview 
• Collaborating with First Nations Communities to Enhance Hepatitis C Care Kate Dunn
• Q&A

• Thinking outside the Box for HCV: Treat to Cure and Eliminate + Q&A Margaret Hellard 
• Oral Presentation: NEW HIV, HCV AND HBV INFECTIONS ATTRIBUTED TO UNSAFE MEDICAL INJECTIONS IN LOW AND MIDDLE-INCOME COUNTRIES: AN ANALYSIS BASED ON DEMOGRAPHIC AND HEALTH SURVEYS  + Q&A  Adelina Artenie
• IMPACT OF PHARMACIST-LED HEPATITIS C SERVICE ON CURE RATES IN A FEDERALLY QUALIFIED HEALTH CENTER + Q&A Elma Abdullah
• Pharmacology of long-acting HCV therapeutics Andrew Owen
• Introductory Talk and Panel + Q&A Niklas Luhmann

• Restoring immunity to cure hepatitis B Ulrike Protzer
  Immunologic prescription for a vaccine to prevent chronic hepatitis C Andrea Cox 
• Oral Presentation: MYELOID CELLS SUPPORT THE INDUCTION OF AUTO-AGGRESSIVE CD8 T CELLS IN CHRONIC HEPATITIS B Wei Ting (Jonah) Lin
• Oral Presentation: RNAI SYNERGIED WITH PEGIFNα IN CHRONIC HEPATITIS B TREATMENT VIA AUGMENTED EPIGENETIC REPRESSION OF CCCDNA AND ALTERED T/B CELL CROSSTALK Zhenghon Yuan
• Oral Presentation
• Q&A

• Novel Biomarkers and Point of Care Tests for HBV management Lung Yi Mak
• Application of Artifical Intelligence in Viral Hepatitis Terry Yip
• Oral Presentation: PERFORMANCE OF ELECSYS ANTI-HEV IGG AND IGM ASSAYS FOR THE DETECTION OF ACUTE, RECENT, OR PAST HEPATITIS E VIRUS INFECTION Korbinian Kienle
• Oral Presentation: REAL-WORLD IMPLEMENTATION OF POINT-OF-CARE (POC) HCV RNA TESTING IN A MOBILE UNIT IN HOMELESS ENCAMPMENTS AND SHELTERS IN ONTARIO, CANADA: IMPACT ON THE CASCADE OF CARE Lindsay Myles
• Oral Presentation: NON-INVASIVE METHODS FOR DIAGNOSING PORTAL HYPERTENSION AND VARICEAL BLEEDING DUE TO LIVER CIRRHOSIS SECONDARY TO NAFLD Nebyu Yonas Shanka
• Q&A

• Novel Interventions to Facilitate Hep C Elimination in Rural Settings (Integrating work on larger scale, randomized control trials, rural home test kits) Jennifer Havens
• Addressing Barriers to Hepatitis B Screening in Low and Middle Income Settings Tanwandee Tawasek 
• Oral Presentation: MODELING HEPATITIS C VIRUS ELIMINATION IN THE UNITED STATES: ARE WE ON TRACK TO REACH INCIDENCE TARGETS? Natasha Martin
  PROGRESS TOWARD HEPATITIS C ELIMINATION IN HIGH-INCOME COUNTRIES Homie Razavi
• Oral Presentation: A COMPARATIVE ANALYSIS OF NATIONAL HBV ELIMINATION POLICIES, PROGRAMS, AND PROGRESS ACROSS INCOME LEVELS Jana Manning
• Oral Presentation: MODELLING THE IMPACT AND COST-EFFECTIVENESS OF SCALING UP OF HCV CASE FINDING AND TREATMENT FOR ACHIEVING ELIMINATION AMONG PEOPLE WHO INJECT DRUGS IN ENGLAND Peter Vickerman
• Q&A 

• Alcohol and Viral Hepatitis: How Much is too Much? Jennifer Flemming
• Risk of HCC in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and Viral Hepatitis Mindie Nguyen
• Oral Presentation: LOW VIRAL LOAD ASSOCIATED WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AMONG PEOPLE LIVING WITH HEPATITIS B VIRUS (PLWHB) IN A DIVERSE CENTRAL LONDON CLINIC Emily Martyn
• Oral Presentation: COMMON COMORBIDITIES IN PATIENTS WITH HEPATITIS C Hussain Asgarali
• Q&A

• HCV : Improving care after HCV diagnosis and after HCV Cure  Jennifer Price
• Treatment of HCV in Context of HCC - Remaining Challenges in 2025 Norah Terrault
• Oral Presentation: A NATIONAL PROGRAM TO SCALE-UP POINT-OF-CARE TESTING AND TREATMENT FOR HEPATITIS C INFECTION IN AUSTRALIA, 2022-2024 Jason Grebely
• Oral Presentation: HOW MUCH DAA TREATMENT IS ENOUGH? OUTCOMES FROM A LARGE CASE SERIES OF HCV TREATMENT INTERRUPTIONS Astha Kanani
• Oral Presentation: ADHERENCE AND DOSE INTERRUPTIONS OF GLECAPREVIR/PIBRENTASVIR IN CHRONIC HCV PATIENTS WITH MULTIPLE COMORBIDITIES AND ON CONCOMITANT MEDICATIONS Jordan Feld
• Q&A

• WHO Progress, and Next Steps toward hepatitis elimination Funmi Lesi 
• Spain Javier Garcia-Samaniego
• South Korea Su Jong Yu
• Pakistan Saeed Hamid 
• Plans, policies and progress toward  hepatitis elimination: Findings from 33 national profiles  Lindsey Hiebert 
• Q&A

• CAR-T cells in liver transplantation Elmar Jaeckel
  Gene correction in the liver using CRISPR  Alexander Ploss
• CRMA-1001 AN EPIGENETIC EDITOR FOR THE TREATMENT OF CHRONIC HEPATITIS B Yesseinia Anglero-Rodriguez
• PBGENE-HBV DEFINITIVE PRECLINICAL TOXICOKINETIC AND TOXICOLOGY DATA ENABLES ADVANCEMENT TO CLINICAL TRIALS FOR A POTENTIALLY CURATIVE GENE EDITING TREATMENT FOR CHRONIC HEPATITIS B Emily Harrison
• INHIBITING HDV BY ADENINE BASE EDITING OF HEPATITIS B SURFACE ANTIGEN Anuj Kumar
• Q&A
   

• Immunocompromised Patients and Viral Hepatitis Management Karen Doucette
• Management of Children with Viral Hepatitis (i.e., Immuntolerant or High Replicative, Non-Inflammatory) Ravi Jahvari
• Oral Presentation: HEPATITIS B REACTIVATION AND TRANSMISSION OUTCOMES IN KIDNEY TRANSPLANTATION: A RETROSPECTIVE COHORT STUDY Imran Hasanoglu
• Oral Presentation: WHAT DO WE KNOW ABOUT GENDER AND AGE IN GLOBAL HEPATITIS C TREATMENT WITH SOF/VEL?  A STUDY OF 7,000 PATIENTS IN ASIA, LATIN Fatima Higuera
• Oral Presentation: PREVALENCE OF VIRAL HEPATITIS IN SEXUAL MINORITIES IN THE UNITED STATES: A NATIONAL COHORT STUDY Tzu-Hao Lee
• Q&A

Moderator: Jason Grebely

• The Role of Policy Development in the Access to New Prevention Screening & Treatment 
• How to Implement New Diagnostic Technologies in the Field Boatemaa Ntiri-Reid
• Access to the Latest Therapies Liudmyla Maistat 
• The Roles of Communities of Practice: To Implement New Technologies & Strategies Sanjeev Arora
• Panel Discussion + Q&A

Moderator: John Ward

• Australia Greg Dore 
• UK David Leeman
• Spain Camila Picchio 
• Africa Ponsianoo Ocama 
• Morrocco Ibtissam Khoudri
• China Cui Fuqiang
• Panel + Q&A